» Articles » PMID: 24552807

Senescence-accelerated OXYS Rats: a Model of Age-related Cognitive Decline with Relevance to Abnormalities in Alzheimer Disease

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2014 Feb 21
PMID 24552807
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Senescence-accelerated OXYS rats are an experimental model of accelerated aging that was established from Wistar stock via selection for susceptibility to cataractogenic effects of a galactose-rich diet and via subsequent inbreeding of highly susceptible rats. Currently, we have the 102nd generation of OXYS rats with spontaneously developing cataract and accelerated senescence syndrome, which means early development of a phenotype similar to human geriatric disorders, including accelerated brain aging. In recent years, our group found strong evidence that OXYS rats are a promising model for studies of the mechanisms of brain aging and neurodegenerative processes similar to those seen in Alzheimer disease (AD). The manifestation of behavioral alterations and learning and memory deficits develop since the fourth week of age, i.e., simultaneously with first signs of neurodegeneration detectable on magnetic resonance imaging and under a light microscope. In addition, impaired long-term potentiation has been demonstrated in OXYS rats by the age of 3 months. With age, neurodegenerative changes in the brain of OXYS rats become amplified. We have shown that this deterioration happens against the background of overproduction of amyloid precursor protein (AβPP), accumulation of β-amyloid (Aβ), and hyperphosphorylation of the tau protein in the hippocampus and cortex. The development of AMD-like retinopathy in OXYS rats is also accompanied by increased accumulation of Aβ in the retina. These published data suggest that the OXYS strain may serve as a spontaneous rat model of AD-like pathology and could help to decipher the pathogenesis of AD.

Citing Articles

Emerging insights in senescence: pathways from preclinical models to therapeutic innovations.

Mansfield L, Ramponi V, Gupta K, Stevenson T, Mathew A, Barinda A NPJ Aging. 2024; 10(1):53.

PMID: 39578455 PMC: 11584693. DOI: 10.1038/s41514-024-00181-1.


The Expression of Genes , , and in Distinct Regions of the Heart and Its Possible Contribution to the Development of Hypertension.

Perepechaeva M, Stefanova N, Grishanova A, Kolosova N Biomedicines. 2024; 12(10).

PMID: 39457686 PMC: 11505345. DOI: 10.3390/biomedicines12102374.


Adenylyl cyclase 2 expression and function in neurological diseases.

Gray M, Nash K, Yao Y CNS Neurosci Ther. 2024; 30(7):e14880.

PMID: 39073001 PMC: 11284242. DOI: 10.1111/cns.14880.


Postnatal Maturation of the Blood-Brain Barrier in Senescence-Accelerated OXYS Rats, Which Are Prone to an Alzheimer's Disease-like Pathology.

Rudnitskaya E, Kozlova T, Burnyasheva A, Peunov D, Tyumentsev M, Stefanova N Int J Mol Sci. 2023; 24(21).

PMID: 37958635 PMC: 10648128. DOI: 10.3390/ijms242115649.


The Rat Brain Transcriptome: From Infancy to Aging and Sporadic Alzheimer's Disease-like Pathology.

Stefanova N, Kolosova N Int J Mol Sci. 2023; 24(2).

PMID: 36674977 PMC: 9865438. DOI: 10.3390/ijms24021462.


References
1.
Kozhevnikova O, Korbolina E, Ershov N, Kolosova N . Rat retinal transcriptome: effects of aging and AMD-like retinopathy. Cell Cycle. 2013; 12(11):1745-61. PMC: 3713133. DOI: 10.4161/cc.24825. View

2.
Markova E, Obukhova L, Kolosova N . Activity of cell immune response and open field behavior in Wistar and OXYS rats. Bull Exp Biol Med. 2004; 136(4):377-9. DOI: 10.1023/b:bebm.0000010957.87077.ae. View

3.
Loeffler D, Camp D, Bennett D . Plaque complement activation and cognitive loss in Alzheimer's disease. J Neuroinflammation. 2008; 5:9. PMC: 2292690. DOI: 10.1186/1742-2094-5-9. View

4.
Kaarniranta K, Salminen A, Haapasalo A, Soininen H, Hiltunen M . Age-related macular degeneration (AMD): Alzheimer's disease in the eye?. J Alzheimers Dis. 2011; 24(4):615-31. DOI: 10.3233/JAD-2011-101908. View

5.
Streit W, Xue Q . Life and death of microglia. J Neuroimmune Pharmacol. 2009; 4(4):371-9. DOI: 10.1007/s11481-009-9163-5. View